(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of 129.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Abivax Sa's revenue in 2025 is $8,977,906.On average, 3 Wall Street analysts forecast ABVX's revenue for 2025 to be $351,086,194, with the lowest ABVX revenue forecast at $297,433,933, and the highest ABVX revenue forecast at $384,951,806. On average, 2 Wall Street analysts forecast ABVX's revenue for 2026 to be $498,154,273, with the lowest ABVX revenue forecast at $297,433,933, and the highest ABVX revenue forecast at $698,874,614.
In 2027, ABVX is forecast to generate $7,761,376,759 in revenue, with the lowest revenue forecast at $6,075,516,154 and the highest revenue forecast at $9,673,895,972.